In a landmark paper, researchers at Stanford University have described a new way to derive human induced pluripotent stem cells (iPSCs) without the use of contaminating mouse feeder cells. Using adipose cells as the starting cell population and mTeSR1, a defined medium that allows the expansion of human embryonic and induced pluripotent stem cells without the use of feeders, the researchers were able to fully reprogram the cells to the pluripotent state.
mTeSR1 is a fully defined medium and is the most widely used feeder-independent method for culturing human pluripotent stem cells, with citations in more than 25 publications.
Image by James Ashburn via Flickr
At the base of the neck is located a reserve of stem cells that could revolutionize the fight against obesity and diabetes. These fat-burning stem cells are the mother cells of brown adipose tissue, and a study coordinated by Italian researcher Saverio Cinti of the Marches region Polytechnic Institute discovered them. The results of the study were presented at the European Obesity Congress in Amsterdam and published in Faseb Journal, the magazine of the Federation of American experimental biology societies.
“It is possible to cultivate these stem cells to grow brown adipose tissue
UCLA stem cell scientists who purified a subset of stem cells from fat tissue and used the stem cells to grow bone discovered that the bone formed faster and was of higher quality than bone grown using traditional methods.
The finding may one day eliminate the need for painful bone grafts that use material taken from patients during invasive procedures.
Adipose, or fat, tissue is thought to be an ideal source of mesenchymal stem cells — cells capable of developing into bone, cartilage, muscle and other tissues — because such cells are plentiful in the tissue and easily obtained through procedures
University at Buffalo researchers will test the effectiveness of using stem cells from donors to treat patients with heart failure.
The National Heart, Lung and Blood Institute has awarded $2 million for the four-year translational animal study.
The results could pave the way for a similar trial in humans and eventually help make stem cell therapy more widely available (…)
New Technology to Increase Efficacy of Adult Stem Cells in COPD Treatment
Entest BioMedical announced today it has filed a second patent application in the area of Chronic Obstructive Pulmonary Disease (COPD). This new patent application builds upon the Company’s previously filed COPD patent application and involves the use of photoceutical devices to target stem cells toward areas impacted by COPD in the lungs.
Steve Josephs, PhD, a Scientific Advisor to the Company stated “that by using photoceutical devices in treating COPD, it is believed stem cells can be focused on areas of the lungs where there is damage. Furthermore, being